Prospective study shows atogepant improves migraine days in chronic migraine patients, indicating effective preventive treatment.
Key Points
Atogepant reduced monthly migraine days by 7.1 days over six months, evidencing its effectiveness in chronic migraine treatment.
Among participants, 53% achieved at least a 50% reduction in monthly migraine days at 24 weeks, highlighting a significant response rate.
Participants experienced improved headache impact scores and reduced acute medication intake, indicating better overall management of their condition.
Despite treatment-emergent adverse events reported by 53%, the benefits of atogepant in treatment-resistant chronic migraine patients were significant.